Suppression der Synthese des Tumornekrosefaktors

Association of HSV reactivation and pro-inflammatory cytokine levels with the severity of stomatitis after BEAM chemotherapy and autologous SCT

“…The choice of these markers was based on results from prior studies demonstrating the presence of increased TNF-α and IL-1 plasma levels during the inflammatory phase of chemotherapy-induced mucositis [2,18]. Based on these findings, a number of clinical studies assessing the efficacy [8], subsequent trials did not confirm these results [3,4,27,28]. Thus, in clinical practice, a causal relationship between the intensity of stomatitis and TNF-α and IL-1 levels could not be established.…”

Long-Term Partial Remission of AutoImmune Thrombocytopenia in a Patient Treated with the Anti-Tumor Necrosis Factor-Alpha Antibody Infliximab for Refractory Fistulizing Crohn’s Disease

“…activation of cytotoxic T cells, stimulation of phagocytosis) [4,5,6]. In contrast to the acute form of autoimmune thrombocytopenia, the chronic form often does not respond to steroids (only about 15–20% of treated patients respond [1, 2]), so that further established therapies, including azathioprine and high-dose intravenous immunoglobulin, are considered before a possible splenectomy [1, 2].…”

“…Due to an acute risk of bleeding, we considered to cancel or postpone the infliximab administration and to treat immune thrombocytopenia with high-dose glucosteroids and/or high-dose intravenous immunoglobulins [1, 2]. Similar to some other forms of autoimmune diseases, such as rheumatoid arthritis, spondylarthropathies, autoimmune hemolytic anemia and lupus nephritis, there is evidence that TNFα is also involved in the pathogenesis of chronic autoimmune thrombocytopenia [4,5,6]. Since few cases of successful treatment of immune thrombocytopenia with anti-TNFα antibodies have been reported, we applied 350 mg infliximab (corresponding to 5 mg infliximab/kg body weight) as intravenous infusion over a period of 2 h. Before infliximab infusion, the patient received intravenous injections of 250 mg prednisolon (SoluDecortin H®) and 2 mg clemastin (Tavegil®).…”

Treatment of chronic inflammatory disease with cytokines and anticytokines

“…Bei gesunden Probanden wurde mit dieser Methode kein TNF-α im Plasma nachgewiesen (29). Im Gegensatz dazu finden sich jedoch hohe Konzentrationen bei verschiedenen infektiösen und chronisch entzündlichen Erkrankungen wie der rheumatoiden Arthritis, Sarkoidose oder Morbus Crohn (12). Die ersten klinischen Pilotstudien mit einem humanisierten, chimären Maus-Antikörper gegen TNF-α (cA2) wurden bei rheumatoider Arthritis durchgeführt.…”